Evidence map›Paper›PMID 38820427›Full record

ArticlePloS one2024

Comparing labour induction outcomes using misoprostol and dinoprostone in term pregnancies: A retrospective study at Kiambu Level 5 Hospital between 2018 and 2020.

Magoma Mwancha-Kwasa, Rashida Admani, Margaret Mbuga, Mary Maina, Jonathan Mwangi, Lucy Ng'ang'a, Margaret Waweru, Sarah Mwangi, Patrick Nyaga, Davis Kamondo and 5 more

Abstract readComparative Study
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Magoma Mwancha-KwasaDepartment of Health, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Rashida AdmaniKiambu Level Five Hospital, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Margaret MbugaKiambu Level Five Hospital, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Mary MainaKiambu Level Five Hospital, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Jonathan MwangiSchool of Pharmacy and Health Sciences, United States International University, Nairobi, Kenya.
Lucy Ng'ang'aKiambu Level Five Hospital, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Margaret WaweruKiambu Level Five Hospital, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Sarah MwangiKiambu Level Five Hospital, County Government of Kiambu, Kiambu, Kiambu County, Kenya.ORCID 0009-0006-2487-8741
Patrick NyagaDepartment of Health, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Davis KamondoDepartment of Health, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Grace Akech OchiengKiambu Level Five Hospital, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Prabhjot Kaur JuttlaFaculty of Health Sciences, School of Medicine, University of Nairobi, Nairobi, Kenya.ORCID 0009-0003-7227-7949
Ryan NyotuDepartment of Health, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Teresia Njoki KimaniDepartment of Health, County Government of Kiambu, Kiambu, Kiambu County, Kenya.
Moses NdirituDepartment of Health, County Government of Kiambu, Kiambu, Kiambu County, Kenya.ORCID 0000-0002-3219-5274

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Maternal and Perinatal Death Surveillance and Response (MPDSR) was introduced in Kenya in 2016 and implemented at Kiambu Level 5 Hospital (KL5H) three years later in 2019. During a routine MPDSR meeting at KL5H, committee members identified a possible link between the off-label use of 200mcg misoprostol tablets divided eight times to achieve the necessary dose for labour induction (25mcg) and maternal deaths. Following this, an administrative decision was made to switch from misoprostol to dinoprostone for the induction of labour in June of 2019. This study aimed to assess the overall impact of MPDSR as well as the effect of replacing misoprostol with dinoprostone on uterine rupture, maternal and neonatal deaths at KL5H.

methodsWe conducted a retrospective cohort study of women who gave birth at KL5H between January 2018 and December 2020. We defined the pre-intervention period as January 2018-June 2019, and the intervention period as July 2019-December 2020. We randomly selected the records of 411 mothers, 167 from the pre-intervention period and 208 from the intervention period, all of whom were induced. We used Bayes-Poisson Generalised Linear Models to fit the risk of uterine rupture, maternal and perinatal death. 12 semi-structured key person questionnaires was used to describe staff perspectives regarding the switch from misoprostol to dinoprostone. Inductive and deductive data analysis was done to capture the salient emerging themes.

resultsWe reviewed 411 patient records and carried out 12 key informant interviews. Mothers induced with misoprostol (IRR = 3.89; CI = 0.21-71.6) had an increased risk of death while mothers were less likely to die if they were induced with dinoprostone (IRR = 0.23; CI = 0.01-7.12) or had uterine rupture (IRR = 0.56; CI = 0.02-18.2). The risk of dying during childbearing increased during Jul 2019-Dec 2020 (IRR = 5.43, CI = 0.68-43.2) when the MPDSR activities were strengthened. Induction of labour (IRR = 1.01; CI = 0.06-17.1) had no effect on the risk of dying from childbirth in our setting. The qualitative results exposed that maternity unit staff preferred dinoprostone to misoprostol as it was thought to be more effective (fewer failed inductions) and safer, regardless of being more expensive compared to misoprostol.

conclusionWhile the period immediately following the implementation of MPDSR at KL5H was associated with an increased risk of death, the switch to dinoprostone for labour induction was associated with a lower risk of maternal and perinatal death. The use of dinoprostone, however, was linked to an increased risk of uterine rupture, possibly attributed to reduced labour monitoring given that staff held the belief that it is inherently safer than misoprostol. Consequently, even though the changeover was warranted, further investigation is needed to determine the reasons behind the rise in maternal mortalities, even though the MPDSR framework appeared to have been put in place to quell such an increase.

Indexed as

DinoprostoneLabor, InducedMisoprostolOxytocicsAdultFemaleHumansInfant, NewbornMaternal MortalityPerinatal DeathPregnancyRetrospective StudiesUterine RuptureYoung AdultDinoprostoneMisoprostolOxytocics

Identifiers

PMID38820427
PMCPMC11142478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.